Similar articles

• Is it time for a cardiovascular primary prevention trial in the elderly?

  Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Robinson JG, et al. Stroke. 2007 Feb;38(2):441-50. doi: 10.1161/01.STR.0000254602.58896.d2. Epub 2006 Dec 28. Stroke. 2007. PMID: 17194877 Review.
• Prevention trials in Alzheimer disease: one step forward?

  Touchon J, Portet F, Gauthier S. Touchon J, et al. Neurology. 2006 Nov 14;67(9 Suppl 3):S21-2. doi: 10.1212/wnl.67.9_suppl_3.s21. Neurology. 2006. PMID: 17101931 Review.
• Influence and critique of the JUPITER Trial (Statins v no statins for primary prevention of cardiovascular events in patients with normal lipids and elevated C-reactive protein).

  Samson RH, Nair DG. Samson RH, et al. Semin Vasc Surg. 2011 Sep;24(3):172-9. doi: 10.1053/j.semvascsurg.2011.10.005. Semin Vasc Surg. 2011. PMID: 22153029 Review.
• The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

  O'Keefe JH, Carter MD, Lavie CJ, Bell DS. O'Keefe JH, et al. Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Postgrad Med. 2009. PMID: 19491548 Review.
• Will ASCOT change the form of anti-hypertensive therapy?

  Bilous R. Bilous R. Diabet Med. 2006 Jan;23(1):13-4. doi: 10.1111/j.1464-5491.2006.01808.x. Diabet Med. 2006. PMID: 16409559 Review. No abstract available.